References 1 Group EBTC . Tamoxifen for early breast cancer: an overview of the randomized trials . Lancet 1998 ; 351 : 1451 – 1467 . 2 Report from the Breast Cancer Trials Committee SCTO, Edinburgh . Adjuvant tamoxifen
Search Results
The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer
Jennifer A. Ligibel and Eric P. Winer
The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women
Therese B. Bevers
– 5687 . 2. Lamb CA Helguero LA Fabris V . Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma . Breast Cancer Res Treat 2003 ; 79 : 25 – 35 . 3. Sporn MB Dowsett SA Mershon J Bryant HU
Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
Alyssa G. Rieber and Richard L. Theriault
carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases . Lancet 1896 ; 2 : 104 – 107 . 2 Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: report of the National Surgical
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
predictive factors? Can certain subsets of premenopausal women with ER-positive tumors be adequately treated using tamoxifen and/or ovarian suppression and forego adjuvant chemotherapy? What is the optimal strategy for using aromatase inhibitors (AIs) in the
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial
Sherry X. Yang, John Yu, and Molin Wang
, hazard ratio; OFS, ovarian function suppression; PR, progesterone receptor; RFI, recurrence-free interval; RS, recurrence score; Tam, tamoxifen. Figure 2. Recurrence scores and clinical factors for (A) OS and (B) DFS prognosis. Horizontal
NCCN Task Force Report: Breast Cancer in the Older Woman
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
anthracyclines or trastuzumab; 21 – 23 kidney dysfunction and capecitabine; 16 preexisting neuropathy and taxanes; 24 history of thromboembolism and tamoxifen (venous thromboembolism) or bevacizumab (arterial thromboembolism); 25 , 26 and osteoporosis and
Barriers to the Use of Breast Cancer Risk Reduction Therapies
Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster
). BCPT randomized women to receive tamoxifen or placebo, and results showed that the tamoxifen arm had a significant reduction in the risk of developing an estrogen receptor (ER)–positive tumor (relative risk [RR], 0.38; 95% CI, 0.28–0.50), and had no
New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer
Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos
). Patients who received tamoxifen or with depression/anxiety were more likely to develop persistent benzodiazepine use at 3 months (OR, 1.93 [95% CI, 1.12–3.33] and 1.74 [CI, 1.01–3.01], respectively). The other subgroup consisted primarily of clonazepam and
NCCN Guidelines Update: Breast Cancer
William Gradishar and Kilian E. Salerno
recent trial data. For premenopausal women at diagnosis, the NCCN Guidelines for Breast Cancer suggest tamoxifen for 5 years, with or without ovarian suppression, or an AI for 5 years combined with ovarian suppression or ablation (category 1). Women who
NCCN Task Force Report: Bone Health in Cancer Care
Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak
, United Kingdom: Blackwell Healthcare Communications; 1997:22–55. b Eastell R, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone density and bone turnover: results of the ‘Arimidex’ (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study